Cue Biopharma

Cue Biopharma is a clinical-stage biopharmaceutical company designing a novel class of injectable biologics to selectively engage and modulate targeted T cells in vivo to transform the treatment of cancer, infectious diseases, and autoimmune disorders. The company's proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), aims to harness the body's intrinsic immune system without the need for ex vivo manipulation.